New Search

If you are not happy with the results below please do another search

1122 search results for:

421

Insight into clinical sample and consent tracking

Clinical specimens, clinical trial samples and the information associated with them are precious resources that require careful curation. CLI caught up with David Kaye [Vice President and General Manager of BioFortis (a Q2 Solutions company)] to find out more about what this entails.

422

Detection of intrathecal antibody synthesis in CNS diseases

The investigation of antibodies against pathogenic agents in cerebrospinal fluid (CSF) samples is part of the diagnostic work up in acute or chronic inflammatory processes of the central nervous system. This article describes the analysis of intrathecally produced antibodies in CSF and the interpretation of the results.

424

Minimizing the number of false positives in dexamethasone suppression testing for the diagnosis of Cushing’s syndrome

Cushing’s syndrome is related to high production of cortisol and, without timely treatment, it can lead to complications such as heart attacks, strokes and type 2 diabetes. The condition can be diagnosed using a dexamethasone suppression test, which involves tracking the effects of this glucocorticoid medication on cortisol levels. Since the absorption of dexamethasone depends […]

425

Next-generation apo(a) standardization: why, when and how?

There is a revival of the genetically determined cardiovascular risk factor Lp(a). Yet, it is one of the most complicated clinical chemistry parameters, and up to 2-fold variation in measurement results may be observed between in vitro diagnostic tests. A next-generation reference measurement system based on mass spectrometry – and endorsed by the International Federation […]